Multiple U.S. IPOs have priced in recent weeks, including Aspen Neuroscience and Bambusa Therapeutics in late October and Narragansett Bancorp in early November, while additional offerings such as Rezera Inc. and vVardis Holding remain scheduled for mid-November pricing. The pipeline shows robust activity, with more than 20 new S-1 and F-1 filings in the past 30 days alongside several effective registrations. Equity market strength, particularly in AI and biotech sectors, has supported valuations, as evidenced by Anthropic’s amended filing targeting a potential late-2026 launch. With roughly eight weeks remaining until year-end, the combination of filed deals, active underwriter marketing, and favorable trading conditions positions additional IPOs to occur before 2027.